Chemopreventive effects of resveratrol and resveratrol derivatives

Authors

  • Thomas Szekeres,

    1. Institute for Laboratory Medicine, Department for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria.
    Search for more papers by this author
  • Philipp Saiko,

    1. Institute for Laboratory Medicine, Department for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria.
    Search for more papers by this author
  • Monika Fritzer-Szekeres,

    1. Institute for Laboratory Medicine, Department for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria.
    Search for more papers by this author
  • Bob Djavan,

    1. Department of Urology, New York University, New York, New York.
    Search for more papers by this author
  • Walter Jäger

    1. Department of Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Vienna, Austria
    Search for more papers by this author

Address for correspondence: Thomas Szekeres, M.D., Ph.D., Institute for Laboratory Medicine, Medical University of Vienna, General Hospital of Vienna, 5H, Waehringer Guertel 18–20, A-1090 Vienna, Austria. thomas.szekeres@meduniwien.ac.at

Abstract

Resveratrol is considered to have a number of beneficial effects. Recently, our group modified the molecule and synthesized a number of compounds with different biochemical effects. Polymethoxy and polyhydroxy derivatives of resveratrol were shown to inhibit tumor cell growth in various cell lines and inflammation pathways (cyclooxygenases activity), in part more effectively than resveratrol itself. One lead compound (hexahydroxystilbene, M8) turned out to be the most effective inhibitor of tumor cell growth and of cyclooxygenase 2 activity. M8 was then studied in two different human melanoma mouse models. This novel resveratrol analog was able to inhibit melanoma tumors in a primary tumor model alone and in combination with dacarbacine, an anticancer compound that is used for melanoma treatment. We also tested the development of lymph node metastasis in a second melanoma model and again M8 successfully inhibited the tumor as well as the size and weight of lymph node metastasis. Hydroxylated resveratrol analogs therefore represent a novel class of anticancer compounds and promising candidates for in vivo studies.

Ancillary